Study shows cardiac troponin measurement using ultra-sensitive Singulex cTnI test can identify the presence and severity of coronary artery disease in stable, symptomatic outpatients

▤ Summary

ALAMEDA, Calif., March 21, 2018 /PRNewswire/ -- Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singulex cTnI assay and Single Molecule Counting technology can independently predict moderate and severe coronary disease (CAD), suggesting its clinical utility for accurate, safe and cost-effective evaluation of patients in an outpatient setting, according to a study appearing in the March issue of the Journal of the American College of Cardiology Imaging. Cardiac troponin is a well-established biomarker currently used in hospital Emergency Departments to help diagnose myocardial infarction (MI) in patients who present with acute chest pain. Findings from The Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial shed light on the broader potential of troponin measurement in the chronic setting. "Chest discomfort is one of the most commonly-encountered complaints in outpatient medicine, and represents a major diagnostic challenge as patients often present with a broad range of non-specific symptoms or signs," said James Januzzi, Jr, MD, Physician in the Cardiology Division at Massachusetts General Hospital, the Hutter Family Professor of Medicine at Harvard Medical School, and Senior Cardiometabolic Trials Faculty at the Baim Institute for Clinical Research. Investigators found concentrations of the biomarker cardiac troponin I (cTnI) associated with presence and severity of coronary artery calcium (CAC) and obstructive CAD.

▦ Linked Companies

Singulex

$10M to $25M